1. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial);Agarwal A;BMJ,2020
2. Clinical management protocol. COVID-19. (2020). Accessed: March 12, 2024: http://clinicalestablishments.gov.in/WriteReadData/2801.pdf.
3. A phase II, open label, randomized controlled trial to assess the safety and efficacy of convalescent plasma to limit COVID-19 associated complications in moderate disease. (2020). Accessed. March 14, 2024: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadPublic_NoticesFiles/ICMR%20Convalescent%20plasma%20_....
4. Toolkit updated 01/14/22 COVID-19 convalescent plasma (CCP) under emergency use authorization. (2022). Accessed. December 30, 2022: https://www.aabb.org/docs/default-source/default-document-library/regulatory/toolkit-for-ccp-under-eua.pdf.
5. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants;Weisblum Y;Elife,2020